Skip to content

KYNTRA BIO, INC.: financial reference

Explore KYNTRA BIO, INC. financial histories from SEC filings, with original units, reporting periods, filing dates and downloadable source data.

Context from the filing

The 2021 and 2022 figures for Kyntra Bio come from the historical FibroGen filing. It excludes potential shares because the company reported losses in those periods. Shares are displayed in thousands with inline scale 3; full counts and USD EPS are retained as reported in that filing. These older values have not been rescaled to the later 2025 reverse-split basis. Read the source filing.

Kyntra Bio, formerly FibroGen, reports positive total EPS of $45.37 in 2025, while continuing operations had a loss. Its dilution note explicitly bases the exclusion of potential shares on losses from continuing operations in 2024 and 2025; total profit does not establish dilution. Discontinued operations account for the positive 2025 total. This filing retrospectively adjusts share amounts for the June 16, 2025 one-for-25 reverse split and displays weighted-average shares in thousands with inline scale 3. Its 2024 and 2025 values are retained on that reported basis; older filing values are not silently rescaled. Read the source filing.

Reported financial histories

Choose a measure to inspect its definition, complete selected history and filing provenance. Each row shows the latest period available for that selected concept and original unit. Separate currencies and reporting intervals remain separate rows. Coverage dates can differ between concepts. A recent capture does not imply recent accounting coverage; these amounts are not prices.

Latest periods by selected concept and original unit
MeasurePeriod startPeriod endValueUnitFiled
Total assetsAt date2025-12-31119,594,000USD2026-03-16
Total liabilitiesAt date2025-12-31115,119,000USD2026-03-16
Stockholders equityAt date2025-12-31-30,038,000USD2026-03-16
Cash and cash equivalentsAt date2025-12-3147,872,000USD2026-03-16
Net income or loss2025-01-012025-12-31183,452,000USD2026-03-16
Operating cash flow2025-01-012025-12-31-4,774,000USD2026-03-16
Capital expenditure payments2025-01-012025-12-3138,000USD2026-03-16
Revenue2025-01-012025-12-316,440,000USD2026-03-16
Contract revenue excluding tax2025-01-012025-12-316,440,000USD2026-03-16
Financing cash flow2025-01-012025-12-31-86,028,000USD2026-03-16
Investing cash flow2025-01-012025-12-3135,419,000USD2026-03-16
Retained earnings or deficitAt date2025-12-31-1,706,047,000USD2026-03-16
Basic weighted-average shares2025-01-012025-12-314,043,000shares2026-03-16
Diluted weighted-average shares2025-01-012025-12-314,043,000shares2026-03-16
Basic earnings per share2025-01-012025-12-3145.37USD/shares2026-03-16
Diluted earnings per share2025-01-012025-12-3145.37USD/shares2026-03-16
Income tax expense or benefit2025-01-012025-12-31-90,000USD2026-03-16
Net property, plant and equipmentAt date2024-12-310USD2025-03-17
Share-based compensation expense2025-01-012025-12-316,576,000USD2026-03-16
Operating income or loss2025-01-012025-12-31-45,895,000USD2026-03-16
Current assetsAt date2025-12-3199,073,000USD2026-03-16
Interest expense2025-01-012025-12-318,759,000USD2026-03-16
Current liabilitiesAt date2025-12-3129,242,000USD2026-03-16
Current accounts payableAt date2025-12-313,745,000USD2026-03-16
Net current accounts receivableAt date2025-12-31216,000USD2026-03-16
Operating expenses2020-01-012020-12-31368,199,000USD2021-03-01
Net inventoryAt date2025-12-313,743,000USD2026-03-16
Cost of revenue2025-01-012025-12-31556,000USD2026-03-16
Selling, general and administrative expense2025-01-012025-12-3127,709,000USD2026-03-16
Research and development expense2025-01-012025-12-3123,517,000USD2026-03-16

Inspect the source

Entity
KYNTRA BIO, INC. / CIK 0000921299
Captured
2026-09-20T05:08:01.696Z
SEC response SHA-256
60313741a614d381e73fc033725566bd06ee27593e71b4e95a10100fd7a817db

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000921299.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))